皮膚がんの米国・カナダ市場2020-2027:検査種類別(皮膚生検、皮膚鏡検査)、施設タイプ別、年齢別

◆英語タイトル:U.S. & Canada Skin Cancer Dermatology Market Size, Share & Trends Analysis Report By Test Type (Skin Biopsy, Dermatoscopy), By Facility Type (Stand-alone, Hospitals), By Age Group, And Segment Forecasts, 2020 - 2027
◆商品コード:GV20JN010
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2020年5月
◆ページ数:116
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2週間)
◆調査対象地域:米国、カナダ
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥618,800見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥722,800見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥930,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

U.S. & Canada Skin Cancer Dermatology Market Growth & Trends
The U.S. and Canada skin cancer dermatology market size is expected to reach around a value of USD 2.2 billion and 0.7 billion respectively by 2027, according to a new report by Grand View Research, Inc. The markets are anticipated to register a CAGR of 5.2% and 6.3% respectively, during the forecast period. Technological advancements and increasing prevalence of skin cancer are anticipated to fuel the growth.

The growing usage of smartphones and the development of smartphone compatible dermatoscopes are the factors anticipated to fuel the market growth. According to the Canadian Radio-television and Telecommunications Commission data, the percentage of Canadians using a smartphone increased from 73% in 2015 to 78% in 2017, thus indicating high potential for teledermatology in the country.

In addition, ongoing research activities for advancements in the dermatology field are anticipated to drive the growth of the market in U.S and Canada. For instance, according to the study published by Nature Journal, Deep Convolutional Neural Networks (CNN) classified the various skin cancers with a competence level comparable to a dermatologist, thus highlighting the potential of Artificial Intelligence (AI) in the field of dermatology.

Inappropriate use of ABCD criteria by Medical necessity auditors is one of the major concerns of dermatologists. For instance, some of the melanoma positive biopsies have been ruled as ‘medically unnecessary’ due to lack of medical documentation of ABCD or signs and symptoms. The ABCD tool was primarily designed for public education and not an important aspect of the physician’s note.

U.S. & Canada Skin Cancer Dermatology Market Report Highlights

• Skin biopsy is the most widely used test for skin cancer and thus, accounted for the largest market share in 2019

• Diagnostic imaging is anticipated to witness rapid growth over the forecast period due to the introduction of advanced imaging and non-invasive diagnostic techniques

• The 40-59 segment held the largest market share in 2019 while the 20-39 segment is anticipated to witness lucrative growth over the forecast period

• Teledermatology programs such as DermaGO, ACCESSDERM are anticipated to improve patient access in the U.S. and Canada

• Hospital OPD segment held a significant share of the U.S. and Canada skin cancer dermatology market in 2019 owing to the presence of public insurance systems is expected to enhance the patient influx in this setting

• Age and gender of the dermatologists significantly affect the type of practice, practice location and work hours.

• Some of the key market players are Firefly; SkinIO, Canfield Scientific, Inc., FotoFinder Systems, Inc., 3Gen, MetaOptima, Agilent Technologies, SkinVision, Speclipse, Inc., Skin Analytics.

【レポートの目次】

Table of Contents

Chapter 1 Methodology and Scope
1.1 Segment Market Scope
1.2 Estimates and Forecast Timeline
1.3 Research Methodology
1.3.1 Information procurement
1.3.2 Purchased database:
1.3.3 GVR’s Internal Database
1.3.4 Secondary sources:
1.3.5 Primary Research:
1.4 List of Primary Sources
1.5 Information Or Data Analysis
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Approach 1: Bottom up Approach
1.7.2 Approach 2: Procedure Volume Approach
1.8 Objectives
1.8.1 Objective 1:
1.8.2 Objective 2:
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 U.S. Market Variable Analysis
3.2.1 Market driver analysis
3.2.1.1 Increase in the prevalence of skin cancer
3.2.1.2 Exposure to ultraviolet radiation
3.2.1.3 Constant technological advancements in skin cancer diagnostic tests
3.3 Canada Market Variable Analysis
3.3.1 Market driver analysis
3.3.1.1 Increasing incidence of melanoma in Canada
3.3.1.2 Technological advancements
3.3.1.3 Increasing awareness campaigns and supportive government initiatives
3.3.2 U.S. Market restraint analysis
3.3.2.1 Lack of universal health coverage
3.3.3 Canada Market restraint analysis
3.3.3.1 Shortage of medical resources and limited access to healthcare.
3.4 Penetration & Growth Prospect Mapping
3.4.1 U.S. Penetration & Growth Prospect Mapping, By Test Type
3.4.2 Canada Penetration & Growth Prospect Mapping, By Test Type
3.5 Business Environment Analysis tools
3.5.1 SWOT Analysis, by PEST
3.5.2 Porter’s five forces analysis
3.5.3 U.S. & Canada Dermatology Market: Competitive insight
3.5.3.1 Role of concierge medicine/boutique medicine in the dermatology space
3.5.3.2 Advantages of Concierge Medicine:
3.5.3.3 Disadvantages of Concierge Medicine:
3.5.3.4 Role of nurse practitioners and physician assistants in the value chain of skin cancer screening
3.5.3.5 Technological Advancements
3.5.3.6 Decision support systems & Dermatology software
3.5.3.7 Artificial intelligence in dermatology
3.5.3.8 Applications:
Chapter 4 U.S. Dermatology Market: Segment Analysis by Test Type
4.1 U.S. Dermatology Market: Test Type Movement Analysis
4.2 Skin Biopsy
4.2.1 Skin Biopsy market estimates and forecasts, 2016 – 2027 (USD Million)
4.3 Dermatoscopy
4.3.1 Dermatoscopy market estimates and forecasts, 2016 – 2027 (USD Million)
4.4 Diagnostic Imaging
4.4.1 Diagnostic imaging market estimates and forecasts, 2016 – 2027 (USD Million)
4.5 Lymph Node Biopsy
4.5.1 Lymph Node Biopsy market estimates and forecasts, 2016 – 2027 (USD Million)
Chapter 5 Canada Dermatology Market: Segment Analysis by Test Type
5.1 Canada Dermatology Market: Test Type Movement Analysis
5.2 Skin Biopsy
5.2.1 Skin Biopsy market estimates and forecasts, 2016 – 2027 (USD Million)
5.3 Dermatoscopy
5.3.1 Dermatoscopy market estimates and forecasts, 2016 – 2027 (USD Million)
5.4 Diagnostic Imaging
5.4.1 Diagnostic imaging market estimates and forecasts, 2016 – 2027 (USD Million)
5.5 Lymph Node Biopsy
5.5.1 Lymph Node Biopsy market estimates and forecasts, 2016 – 2027 (USD Million)
Chapter 6 U.S. Dermatology Market: Segment Analysis by Facility Type
6.1 U.S. Dermatology Market: Facility Type Movement Analysis
6.2 Standalone Practices
6.2.1 Standalone Practices market estimates and forecasts, 2016 – 2027 (USD Million)
6.3 Multispecialty Clinics
6.3.1 Multispecialty Clinics market estimates and forecasts, 2016 – 2027 (USD Million)
6.4 Dermatology Groups
6.4.1 Dermatology Groups market estimates and forecasts, 2016 – 2027 (USD Million)
6.5 Hospital Outpatient Departments
6.5.1 Hospital Outpatient Departments market estimates and forecasts, 2016 – 2027 (USD Million)
6.6 Others (Integrated Delivery Network)
6.6.1 Others (Integrated Delivery Network) market estimates and forecasts, 2016 – 2027 (USD Million)
Chapter 7 Canada Dermatology Market: Segment Analysis by Facility Type
7.1 Canada Dermatology Market: Facility Type Movement Analysis
7.2 Standalone Practices
7.2.1 Standalone Practices market estimates and forecasts, 2016 – 2027 (USD Million)
7.3 Multispecialty Clinics
7.3.1 Multispecialty Clinics market estimates and forecasts, 2016 – 2027 (USD Million)
7.4 Dermatology Groups
7.4.1 Dermatology Groups market estimates and forecasts, 2016 – 2027 (USD Million)
7.5 Hospital Outpatient Departments
7.5.1 Hospital Outpatient Departments market estimates and forecasts, 2016 – 2027 (USD Million)
7.6 Others (Integrated Delivery Network)
7.6.1 Others (Integrated Delivery Network) market estimates and forecasts, 2016 – 2027 (USD Million)
Chapter 8 U.S. Dermatology Market: Segment Analysis by Age-group
8.1 U.S. Dermatology Market: Age-group Movement Analysis
8.2 0-19
8.2.1 0-19 market estimates and forecasts, 2016 – 2027 (USD Million)
8.2.2 Male 0-19 market estimates and forecasts, 2016 – 2027 (USD Million)
8.2.3 Female 0-19 market estimates and forecasts, 2016 – 2027 (USD Million)
8.3 20-39
8.3.1 20-39 Market estimates and forecasts, 2016 – 2027 (USD Million)
8.3.2 Male 20-39 market estimates and forecasts, 2016 – 2027 (USD Million)
8.3.3 Female 20-39 market estimates and forecasts, 2016 – 2027 (USD Million)
8.4 40-59
8.4.1 40-59 Market estimates and forecasts, 2016 – 2027 (USD Million)
8.4.2 Male 40-59 market estimates and forecasts, 2016 – 2027 (USD Million)
8.4.3 Female 40-59 market estimates and forecasts, 2016 – 2027 (USD Million)
8.5 60-64
8.5.1 60-64 Market estimates and forecasts, 2016 – 2027 (USD MILLION)
8.5.2 Male 60-64 market estimates and forecasts, 2016 – 2027 (USD Million)
8.5.3 Female 60-64 market estimates and forecasts, 2016 – 2027 (USD Million)
8.6 65-74
8.6.1 65-74 Market ESTIMATES AND FORECASTS, 2016 – 2027 (USD Million)
8.6.2 Male 65-74 market estimates and forecasts, 2016 – 2027 (USD Million)
8.6.3 Female 65-74 market estimates and forecasts, 2016 – 2027 (USD Million)
8.7 75-84
8.7.1 75-84 Market estimates and forecasts, 2016 – 2027 (USD Million)
8.7.2 Male 75-84 market estimates and forecasts, 2016 – 2027 (USD Million)
8.7.3 Female 75-84 market estimates and forecasts, 2016 – 2027 (USD Million)
8.8 85 & above
8.8.1 85 & above Market estimates and forecasts, 2016 – 2027 (USD Million)
8.8.2 Male 85 & above market estimates and forecasts, 2016 – 2027 (USD Million)
8.8.3 Female 85 & above market estimates and forecasts, 2016 – 2027 (USD Million)
Chapter 9 Canada Dermatology Market: Segment Analysis by Age-group
9.1 Canada Dermatology Market: Age-group Movement Analysis
9.2 0-19
9.2.1 0-19 market estimates and forecasts, 2016 – 2027 (USD Million)
9.2.2 Male 0-19 market estimates and forecasts, 2016 – 2027 (USD Million)
9.2.3 Female 0-19 market estimates and forecasts, 2016 – 2027 (USD Million)
9.3 20-39
9.3.1 20-39 Market estimates and forecasts, 2016 – 2027 (USD Million)
9.3.2 Male 20-39 market estimates and forecasts, 2016 – 2027 (USD Million)
9.3.3 Female 20-39 market estimates and forecasts, 2016 – 2027 (USD Million)
9.4 40-59
9.4.1 40-59 Market estimates and forecasts, 2016 – 2027 (USD Million)
9.4.2 Male 40-59 market estimates and forecasts, 2016 – 2027 (USD Million)
9.4.3 Female 40-59 market estimates and forecasts, 2016 – 2027 (USD Million)
9.5 60-64
9.5.1 60-64 Market estimates and forecasts, 2016 – 2027 (USD Million)
9.5.2 Male 60-64 market estimates and forecasts, 2016 – 2027 (USD Million)
9.5.3 Female 60-64 market estimates and forecasts, 2016 – 2027 (USD Million)
9.6 65-74
9.6.1 65-74 Market estimates and forecasts, 2016 – 2027 (USD Million)
9.6.2 Male 65-74 market estimates and forecasts, 2016 – 2027 (USD Million)
9.6.3 Female 65-74 market estimates and forecasts, 2016 – 2027 (USD Million)
9.7 75-84
9.7.1 75-84 Market estimates and forecasts, 2016 – 2027 (USD Million)
9.7.2 Male 75-84 market estimates and forecasts, 2016 – 2027 (USD Million)
9.7.3 Female 75-84 market estimates and forecasts, 2016 – 2027 (USD Million)
9.8 85 & above
9.8.1 85 & above market estimates and forecasts, 2016 – 2027 (USD Million)
9.8.2 Male 85 & above market estimates and forecasts, 2016 – 2027 (USD Million)
9.8.3 Female 85 & above market estimates and forecasts, 2016 – 2027 (USD Million)
Chapter 10 Competitive Analysis
10.1 Company Profiles
10.1.1 Firefly
10.1.1.1 Company overview
10.1.1.2 Financial performance
10.1.1.3 Product Benchmarking
10.1.2 SkinIO
10.1.2.1 Company overview
10.1.2.2 Financial performance
10.1.2.3 Product Benchmarking
10.1.2.4 Strategic Initiative
10.1.3 Canfield Scientific, Inc.
10.1.3.1 Company overview
10.1.3.2 Financial performance
10.1.3.3 Product Benchmarking
10.1.3.4 Strategic Initiative
10.1.4 FotoFinder Systems, Inc.
10.1.4.1 Company overview
10.1.4.2 Financial performance
10.1.4.3 Product Benchmarking
10.1.5 3GEN
10.1.5.1 Company overview
10.1.5.2 Financial performance
10.1.5.3 Product Benchmarking
10.1.6 MetaOptima
10.1.6.1 Company overview
10.1.6.2 Financial performance
10.1.6.3 Product Benchmarking
10.1.6.4 Strategic Initiative
10.1.7 Agilent Technologies
10.1.7.1 Company overview
10.1.7.2 Financial performance
10.1.7.3 Product Benchmarking
10.1.7.4 Strategic Initiative
10.1.8 SkinVision
10.1.8.1 Company overview
10.1.8.2 Financial performance
10.1.8.3 Product Benchmarking
10.1.9 Speclipse, INC.
10.1.9.1 Company overview
10.1.9.2 Financial performance
10.1.9.3 Product Benchmarking
10.1.10 Skin Analytics
10.1.10.1 Company overview
10.1.10.2 Financial performance
10.1.10.3 Product Benchmarking

List of Tables

Table 1 List of secondary sources
Table 2 U.S. skin cancer dermatology market, by facility type, 2016 - 2027 (USD Million)
Table 3 U.S. skin cancer dermatology market, by test type, 2016 - 2027 (USD Million)
Table 4 U.S. skin cancer dermatology market, by age group, 2016 - 2027 (USD Million)
Table 5 Canada skin cancer dermatology market, by facility type, 2016 - 2027 (USD Million)
Table 6 Canada skin cancer dermatology market, by test type, 2016 - 2027 (USD Million)
Table 7 Canada skin cancer dermatology market, by age group, 2016 - 2027 (USD Million)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[皮膚がんの米国・カナダ市場2020-2027:検査種類別(皮膚生検、皮膚鏡検査)、施設タイプ別、年齢別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆